Alan Main's Email & Phone

Dr. Main has been executive vice president of pharmaceutical research since February 2007 and served as senior vice president from July 2001 to February 2007. Dr. Main established the Medicinal Chemistry operations based in Princeton, New Jersey which are responsible for the design, synthesis, and preclinical testing of all of Lexicon's small molecule drug candidates that may enter human clinical trials. In addition, Dr. Main has played a key role the design and implementation of the company's scientific strategy and prioritization of Lexicon's small molecule drug discovery portfolio. Prior to joining Lexicon, Dr. Main was president and chief executive officer of Coelacanth Corporation, a leader in using proprietary chemistry technologies to rapidly discover new chemical entities for drug development. Lexicon acquired Coelacanth Corporation in July 2001 to bring together the powerful biology and chemistry technologies necessary to create a revolutionary new pharmaceutical company. Prior to Coelacanth, Dr. Main spent more than 20 years in the discovery and development of novel drugs at Novartis Pharmaceuticals Corporation where he was formerly senior vice president, U.S. Research. Dr. Main holds a B.S. from the University of Aberdeen, Scotland, a Ph.D. in organic chemistry from the University of Liverpool, England and completed postdoctoral studies with the Nobel Laureate Prof. R.B. Woodward, at the Woodward Research Institute in Basel, Switzerland.